The global Plant Derived Proteins Market is estimated to reach USD 105 Million by the end of 2022. Growing research and development activities for development of more effective drugs and biologic, especially across countries such as India, China, the USA, and the UK is expected to bolster the growth in the market.
| Attribute | Details |
|---|---|
| Plant Derived Proteins Market Estimated Size in 2022 | USD 105 Million |
| Plant Derived Proteins Market Projected Size in 2029 | USD 184.3 Million |
| Plant Derived Proteins Market Historical CAGR (2014 to 2021) | 7.6% |
| Plant Derived Proteins Market Value-based CAGR (2022 to 2029) | 8.4% |
An exhaustive survey by Future Market Insights (FMI) reveals that the sales in the global plant derived proteins market is projected to exceed USD 184.3 Million, rising at a remarkable CAGR of 8.4% over the forecast period 2022 to 2029.
Based on plant type, the carrot segment is anticipated to exhibit the fastest growth in the market, accounting for more than 46.2% of the plant derived proteins sales by 2022. The plant derived proteins are expected to hold nearly 0.2% of the market share in the global animal and plant based protein market through 2029.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
| Particulars | Details |
|---|---|
| H1, 2021 | 8.89% |
| H1, 2022 Projected | 8.36% |
| H1, 2022 Outlook | 7.86% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 50 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 102 ↓ |
According to Future Market Insights analysis, the global plant derived proteins market expects to drop by 102 Basis Point Share (BPS) in H1-2022 as compared to H1- 2021. Whereas in comparison to H1-2022 projected value, the market during H1-2022 outlook period will show a dip of 50 BPS. The market is subject to regulatory dynamics, pricing fluctuations, and licensing of biologics.
The dip in the BPS values for the market is associated with the emergence of the “free-form” anthology in specialty foods which encloses a gluten and soy-free diet. With the establishment of increased customer choice for gluten and soy-free food products, the market for plant derived products observed a decline in the BPS values.
Conversely, plant derived scaffold proteins for research purposes support cell adhesion and proliferation for regenerative medicine and drug screening by forming critical biomatrices. This has supported promising clinical outlooks, and will pose a positive impact upon the market growth.
The demand in the global plant derived proteins market grew at a CAGR of 7.6% over the past assessment period 2014 to 2021. Plant derived proteins are estimated to create an absolute dollar opportunity of USD 105 Million by the end of 2022.
Plant derived proteins are biologics sourced from tobacco leaves, rice seeds, carrots, and others by molecular farming or cell-culture procedures. These proteins are natural and environmentally sustainable and have significant potential in comparison to other biologics such as microbial and mammalian cells. For instance, the plant derived experimental antibody named ZMapp was reported to be more effective against the Ebola Virus than others.
Hence, advancements in plant expression vectors, glycoengineering, and downstream processing have resulted in increasing use of plants as a superior alternative for biologics production. Driven by this, the sales in the global plant derived proteins are estimated to surpass USD 184.3 Million by the end of 2029.
Rising prevalence of diseases such as diabetes, hepatitis, lymphoma, and Gaucher disease among others across the world has created strong demand for advanced therapeutics. This significant surge in demand for biologics and drugs cannot be met by current production platforms such as microbial and mammalian cells due to their higher cost and limited scalability.
Hence, numerous biopharmaceutical companies are shifting their focus on using animal-free substitutes such as plants owing to their benefit such as eukaryotic protein modification, high scalability, low cost. This is estimated to accelerate the sales of plant derived proteins in the market.
In addition to this, increasing usage of plant derived proteins as raw materials for therapeutic drug production and surging demand for replacement proteins such as insulin and albumin is expected to assist the market to expand at a CAGR of 8.4% over the forecast period 2022 to 2029.
Implementation of stringent guidelines and standards for the production of plant derived proteins by regulatory bodies such as European Medicines Agency (EMA) and Food and Drug Administration (FDA) is hampering the sales in the market.
Also, implementation of ban on the plantation of tobacco in certain countries across Europe, increasing inclination towards biosimilar drugs, and rising incidence of allergic reactions to the drugs produced from genetically engineered plants are factors restraining the growth in the plant derived proteins market.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Growing Emphasis on Launching Novel Therapeutics to Bolster Plant Derived Proteins Sales
Future Market Insights states that the USA is projected to register the fastest growth in the North America plant derived proteins market over the assessment period.
With increasing demand for novel plant derived proteins and other biologics-based drugs, leading players in the country are increasingly focusing on developing novel therapeutics and vaccines. For instance, iBio, Inc., an American biologics manufacturing company, announced using its advanced FastPharming technologies to develop three novel plant-based biologics, IBIO-100, IBIO-200, and IBIO-201 in October 2020.
A slew of such developments and product launches is estimated to bolster the sales of plant derived proteins in the USA market.
Increasing Burden of Diabetes to Fuel the Demand for Plant Derived Recombinant Proteins
As per FMI, India, home to a large number of biotechnology and pharmaceutical companies, is estimated to emerge as the most lucrative plant derived proteins market in South Asia between 2022 and 2029.
The incidence of lifestyle diseases such as diabetes is rapidly increasing owing to the growing fast-paced lifestyle and changing eating habits in India. For instance, according to the International Diabetes Federation, around 74.19 million cases of diabetes between ages 20 to 79 were reported across India, exhibiting a 9.6% rate of incidence in 2021.
As plant derived recombinant proteins such as insulin are extensively being used by diabetic patients to maintain their insulin levels, rising burden of diabetes is expected to elevate the demand for plant derived proteins in India market.
Rising Demand for Cosmetic Products to Bolster the Plant Derived Proteins Sales
The UK is anticipated to register robust growth in the plant derived proteins market in Europe during the forecast period 2022 to 2029, reveals FMI.
Plant derived proteins are gaining immense popularity across the cosmetic industry, owing to their natural, better results, and environmentally-sustainable attributes. On account of this, leading industry players are shifting the preference towards using plant derived proteins from microbial and mammalian cells for the formulation of face creams, serums, and others cosmetic products.
Hence, rapidly increasing demand for cosmetic products on the back of rising emphasis on enhancing facial aesthetics among the population in the UK is projected to bolster the sales of plant derived proteins in the market.
Growing Usage in Breast Cancer Treatment Drugs to Accelerate Plant Derived Therapeutic Proteins Demand
The tobacco segment is estimated to register robust growth, accounting for nearly 39.6% of the plant derived proteins sales through 2022.
Tobacco plant is considered as the ideal host for plant-based engineered proteins owing to its high yield production, rapid plant growth, and ability to produce large amounts of antibodies within 6 to 7 days. In addition to this, increasing use of tobacco derived proteins in breast cancer treatment drugs is favoring sales of plant derives therapeutic proteins in the segment.
Rising Adoption of Novel Cell Culture Platforms to Favor the Plant Derived Proteins Market Growth
On the basis of platform, the global plant derived proteins market is segmented into in-vitro cell culture systems, whole plants, and others. FMI estimates that the in-vitro cell culture systems will account for a significant share in the market over the forecast period. Increasing adoption of novel cell culture platforms such as in-vitro cell culture by biopharmaceutical companies for novel drug production is driving the growth in the segment.
In terms of application, the regenerative medicine-therapeutic agents segment is projected to exhibit rapid growth in the global market through 2029. Growing usage of plant derived proteins as therapeutic agents across the cosmetics industry is the primary factor augmenting sales across the segment.
Therapeutic Proteins Segment to Account for the Maximum Plant Derived Therapeutic Proteins Sales
Therapeutic proteins demand is likely to grow at a rapid pace, accounting for more than 70% of the plant derived proteins sales from 2022 to 2029 in terms of protein.
Demand for plant derived therapeutics proteins such as monoclonal antibodies and vaccines is rapidly increasing on the back of their efficiency in the treatment of diseases. Hence, they are extensively being used for the production of biologics and drugs for the treatment of diseases such as anemia, hepatitis, cancer, hemophilia, and others, which is in turn, facilitating the growth in the segment.
Rising Novel Drug Development Activities to Spur Sales of Plant Derived Proteins
Among end users, biopharmaceutical companies are projected to continue leading the plant derived proteins market, accounting for over 50% of the demand share by the end of assessment period.
Increasing government support in research and development (R&D) activities for the production of more effective therapeutics drugs and shifting preference on using plant-based biologics owing to their high scalability and low cost are factor augmenting the sales across the segment.
Key players in the plant derived proteins market are focusing in adoption expansion strategies such as new product launch and product approval to gain competitive edge. Some of the other companies are aiming at collaboration, merger, and acquisition with other players to expand their market share. For instance,
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2029 |
| Historical Data Available for | 2014 to 2021 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Covered | USA, Canada, Germany, UK, France, Italy, Spain, Poland, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Vietnam, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, South Africa |
| Key Segments Covered | Plant, Protein, Platform, Application, End User, and Region |
| Key Companies Profiled | Amgen Inc; Abbott Laboratories; AstraZeneca; Merck KGaA; Baxter International; Boehringer Ingelheim; Chugai Pharmaceutical; Diasome Pharmaceuticals; Eli Lilly & Company; Protalix Biotherapeutic; F. Hoffmann-La Roche; Generex Biotechnology; GeneScience Pharmaceuticals; Group Biogen Idec Inc; Hualan Biological Engineering; Johnson & Johnson; Kyowa Hakko Kirin; Novo Nordisk |
| Report Coverage | Market Forecast, brand share analysis, competition intelligence, DROT analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The plant derived proteins market is expected to surpass a valuation of USD 105 Million in 2022.
The global plant derived proteins market grew at a 7.6% CAGR over the past assessment period 2014 to 2021.
The plant derived proteins market is expected to register remarkable growth, expanding at 8.4% CAGR between 2022 and 2029.
North America currently leads the global plant derived proteins market, accounting maximum sales through 2029.
South Asia plant derived proteins market will hold a significant share over the assessment period 2022 to 2029.
In terms of plant type, the carrot segment is expected to dominate the global plant derived proteins market, accounting for over 46.2% of the revenue share through 2029.
| Estimated Size, 2024 | USD 4,576.9 million |
|---|---|
| Projected Size, 2034 | USD 10.3 billion |
| Value-based CAGR (2024 to 2034) | 8.5% |
| Market Value in 2021 | USD 588.9 Million |
|---|---|
| Market Value in 2032 | USD 1.5 Billion |
| Market CAGR (2022 to 2032) | 9.0% |
Explore Life Science & Biotechnology Insights
View Reports
Plant Derived Proteins Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
